Tangential Shave Removal of Basal Cell Carcinoma

Abramson, Amanda; Krasny, Mark; Goldman, Glenn D.

doi:10.1111/dsu.12106

Cited by 16 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgical removal is performed either as conventional excision with surgical margins that need to be individually determined based on the recurrence risk (chapter “risk stratification”) and conventional histological examination or as microscopically controlled surgery (systematic margin control to ensure tumor removal both laterally and towards the base). For superficial and smaller BCCs (especially on the trunk and extremities), shave excision may be considered and is associated with comparable cure rates .…”

Section: Risk Stratificationmentioning

confidence: 99%

“…Given the higher likelihood of residual tumor cells in the area treated, recurrence rates are increased, especially in the head/neck region, and may be as high as 83 % for nBCC . Better results, however, can be achieved for lesions on the trunk, in particular for superficial basal cell carcinoma (sBCC) . The aesthetic outcome after shave excision is worse than for conventional surgery.…”

Section: Risk Stratificationmentioning

confidence: 99%

See 1 more Smart Citation

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

SummaryBasal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.

show abstract

Section: Risk Stratificationmentioning

confidence: 99%

Section: Risk Stratificationmentioning

confidence: 99%

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

show abstract

“…For example, while our diagnostic accuracy was >99%, we decided to use 80% from literature to better reflect the average dermatology practice. This number is expected to rise with the increasing using of imaging tools such as dermoscopy 15,17, 18 . In addition, we set the percent of shave removal applicability to 50% of non-MMS-indicated lesions factoring in presenting size <1cm and clinical judgment, but we anticipate this number to be higher as other studies on shave removal have set the size threshold at 1.5–2.5cm without compromising success rate 17,19 .…”

Section: Discussionmentioning

confidence: 99%

Traditional versus streamlined management of basal cell carcinoma (BCC): A cost analysis

Elkin

Chen

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background Facing rising incidence of basal cell carcinoma (BCC) and increasing pressure to contain healthcare spending, physicians need to contemplate cost-effective paradigms for managing BCC. Objective To perform a cost analysis comparing the traditional BCC management scheme to a simplified Detect and Treat (DAT) scheme that eliminates the biopsy prior to initiating definitive treatment. Methods A decision analytic model was developed to compare the costs of traditional BCC management with the DAT scheme, under which qualifying lesions diagnosed clinically were either treated with shave removal or referred to Mohs for on-site histologic check. Values for model parameters were based on literature and our institutional data analysis. Costs were based on 2014 Medicare fee schedule. Results The average cost per lesion with DAT scheme was $449 for non-Mohs-indicated lesions (vs. $566 with traditional management, $117 in savings) and $819 for Mohs-indicated lesions (vs. $864 with traditional management, $45 in savings). The combined weighted average savings per case was $95 (15% of total average cost). Conclusions were similar under various plausible scenarios. Limitations Model parameter values may vary based on individual practices. Conclusions A simplified management strategy eliminating routine pre-treatment biopsy can reduce BCC treatment cost without compromising quality of care.

show abstract

“…Abramson and colleagues published the results of an interesting retrospective study demonstrating a low recurrence rate of basal cell carcinoma (BCC) after tangential shave excision . In this case series, a 2‐ to 3‐mm margin was delineated around the apparent lesion.…”

Section: Some Shortcomings Of Abramson and Colleagues' Studymentioning

confidence: 99%